AAPL   325.12 (+0.55%)
MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Blueprint MedicinesBridgeBio PharmaGlobal Blood TherapeuticsEvotecMirati Therapeutics
SymbolNASDAQ:BPMCNASDAQ:BBIONASDAQ:GBTOTCMKTS:EVTCYNASDAQ:MRTX
Price Information
Current Price$74.60$28.86$66.84$53.90$97.99
52 Week RangeBuyBuyBuyBuyBuy
Beat the Market™ Rank
Overall Score1.61.51.60.51.1
Analysis Score3.53.44.40.02.4
Community Score3.02.33.02.52.9
Dividend Score0.00.00.00.00.0
Ownership Score1.01.00.00.00.0
Earnings & Valuation Score0.60.60.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$91.42$45.10$105.13N/A$113.56
% Upside from Price Target22.54% upside56.27% upside57.29% upsideN/A15.89% upside
Trade Information
Market Cap$3.98 billion$3.51 billion$4.18 billion$4.08 billion$4.26 billion
Beta1.09N/A1.91.071.83
Average Volume572,996590,612802,250337482,026
Sales & Book Value
Annual Revenue$66.51 million$40.56 million$2.11 million$443.55 million$3.34 million
Price / Sales60.7886.361,930.449.191,280.32
CashflowN/AN/AN/A$1.83 per shareN/A
Price / CashN/AN/AN/A29.44N/A
Book Value$9.44 per share$3.83 per share$9.61 per share$6.73 per share$9.67 per share
Price / Book7.907.546.968.0110.13
Profitability
Net Income$-347,690,000.00$-260,590,000.00$-266,770,000.00$99.41 million$-213,260,000.00
EPS($7.27)($2.48)($4.71)N/A($5.69)
Trailing P/E RatioN/AN/AN/A65.79N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-515.98%N/AN/A12.91%-10,983.84%
Return on Equity (ROE)-65.81%N/A-48.56%12.32%-53.25%
Return on Assets (ROA)-46.90%N/A-39.45%5.76%-48.92%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.13%1.03%0.30%0.91%N/A
Current Ratio7.17%14.25%9.07%3.06%12.57%
Quick Ratio7.14%14.25%8.83%2.97%12.58%
Ownership Information
Institutional Ownership Percentage97.95%92.88%N/AN/AN/A
Insider Ownership Percentage4.02%N/A4.20%N/A4.10%
Miscellaneous
Employees2171521712,61763
Shares Outstanding54.19 million121.37 million60.94 million75.61 million43.64 million
Next Earnings Date8/6/2020 (Estimated)8/12/2020 (Estimated)8/5/2020 (Estimated)8/12/2020 (Estimated)8/3/2020 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.